Sanofi-Aventis's Apidra approved in EU for use in children
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's rapid-acting insulin analogue Apidra (insulin glulisine) has been approved by the European Commissionfor the control of hyperglycaemia in adolescents and children aged over six years with diabetes mellitus.